Impact of antirecurrent therapy with antigestagens for uterine fibroids on the breast in reproductive-aged women


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Objective. To evaluate the impact of antirecurrent therapy for uterine fibroids with the use of gynestril (mifepristone 50 mg) on the breast in reproductive-aged women. Subjects and methods. Examinations were made in 110 reproductive-aged women who received antirecurrent therapy with gynestril (mifepristone) at a dose of 50 mg per day in continuous mode for 3 months after laparoscopic myomectomy. Benign breast dysplasia (BBD) was diagnosed based on general clinical examination, check-up, palpation, and ultrasonography of the breast in all the patients before and after gynestril administration, and three months later. Results. Breast examination revealed that prior to gynestril use, 61.82% of the women had subjective signs (mastalgia, mastodynia) of BBD that was objectively verified by ultrasonography in 47.27% of the patients. The use of gynestril was ascertained to be associated with a significant (p < 0.05) decline in the number of women with subjective signs of BBD: from 61.85 to 30% after completion of 3-month therapy and to 31.82% 3 months after treatment termination and in that of women with objective signs of diffuse breast changes: from 40.91 to 21.82% after completion of 3-month therapy and to 19.84% 3 months later. Conclusion. It was established that there was a significant decrease in the detection rate of BBD predominantly as a diffuse form during antirecurrent therapy with gynestril for uterine fibroids.

Texto integral

Acesso é fechado

Sobre autores

Vladislava Novikova

Kuban State Medical University

Email: vladislavan@mail.ru
MD, professor of the Department of Obstetrics, Gynecology and Perinatology, Faculty of Postgraduate Education

Grigory Penzhoyan

Kuban State Medical University

Email: pga05@mail.ru
Doctor of Medical Sciences, Professor, Head of the Department of Obstetrics, Gynecology and Perinatology, Faculty of Advanced Studies and Postgraduate Training of Specialists

Vadim Khorolsky

Kuban State Medical University

Email: vadim23_67@mail.ru
associate professor of the Department of Obstetrics, Gynecology and Perinatology, Faculty of Postgraduate Education

Tatyana Skladanovskaya

Volgograd State Medical University

Email: yanechka2000@yandex.ru
associate professor of the Department of Obstetrics and Gynecology and Perinatology, Faculty of Postgraduate Education

Vladislav Ponomarev

Kuban State Medical University

Email: 11vik@mail.ru
Doctor of Medical Sciences, Professor of the Department of Obstetrics, Gynecology and Perinatology, Faculty of Advanced Studies and Postgraduate Training of Specialists.

Bibliografia

  1. Приказ Минздравсоцразвития России №808н от 2 октября 2009 г. «Об утверждении Порядка оказания акушерско-гинеко логической помощи». [Order of the Health Ministry of Russia №808n dated October 2, 2009. „On approval of the provision of obstetric care.” (in Russian)]
  2. Приказ Министерства здравоохранения Российской Федерации (Минздрав России) от 1 ноября 2012 г. № 572н «Об утверждении Порядка оказания медицинской помощи по профилю акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)». [The Russian Federation Ministry of Health Order (Ministry of Health of Russia) dated November 1, 2012 № 572n „On approval of the provision of medical care on the profile of obstetrics and gynecology (except for the use of assisted reproductive technologies).” (in Russian)].
  3. Идрисова Э.А., Бабгоева О.Х., Коган Е.А., Гуриев Т.Д. Клинико-морфологические особенности фиброзно-кистозной болезни при сочетании с лейомиомой матки и аденомиозом. Российский вестник акушера-гинеколога. 2011; 11(6): 28-32. [Idrisov E.A., Babgoeva O.Kh., Kogan E.A., Guriev T.D. Clinico-morphological features of fibrocystic disease in combination with uterine leiomyoma and adenomyosis. Rossiyskiy vestnik akushera-ginekologa. 2011; 11(6): 28-32. (in Russian)].
  4. Зацепин А.В., Новикова В.А., Васина И.Б. Сравнение эффективности фармакологических методов антирецидивного лечения миомы матки после консервативной миомэктомии. Кубанский научный медицинский вестник. 2012; 2: 88-92. [Zatsepin, AV, Novikov VA, Vasin IB comparing the effectiveness of pharmacological methods of antirecidial treatment of uterine fibroids after conservative myomectomy. Kubanskiy nauchnyiy meditsinskiy vestnik. 2012. 2: 88-92. (in Russian)]
  5. Звичайний М.А., Воронцова А.В., Чилова А.А., Федотовских И.В. Гиперпластический синдром репродуктивной системы у женщин в перименопаузе: тактика консервативной терапии и реабилитации. Гинекология. 2014; 16(1): 44-8. [Zvychayny M.A., Vorontsova A.V., Chilova A.A., Fedotovskaya I.V. Hyperplastic reproductive syndrome in perimenopausal women: the tactics of conservative treatment and rehabilitation. Gynekologiya. 2014; 16(1): 44-8. (in Russian)]
  6. Khan A.T., Shehmar M., Gupta J. K. Uterine fibroids: current perspectives. Int. J. Womens Health. 2014; 6: 95-114. doi: 10.2147/IJWH.S51083.
  7. Wagenfelda A., Saundersb Ph.T.K., Whitakerc L., Critchleyc H.O.D. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin. Ther. Targets. 2016; 20(9): 1045-54. Available at: http:// dx.doi.org/10.1080/14728222.2016.1180368
  8. Obr A.E., Edwards D.P. The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol. Cell. Endocrinol. 2012; 357: 4-17.
  9. Hagan C.R., Knutson T.P., Lange C.A. A common docking domain in progesterone receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Res. 2013; 41(19): 8926-42.
  10. Brisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat. Rev. Cancer. 2013; 13(6): 385-96.
  11. Sartor O., Figg W.D. Mifepristone: antineoplastic studies. Clin. Obstet. Gynecol. 1996; 39(2): 498-505.
  12. Klijn J.G., Setyono Han B., Foekens J.A. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000; 65(10-11): 825-30.
  13. Chabbert-Buffet N., Meduri G., Bouchard P., Spitz I.M. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum. Reprod. Update. 2005; 11(3): 293-307. doi: 10.1093/ humupd/dmi002.
  14. Engman M., Skoog L., Söderqvist G., Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum. Reprod. 2008; 23(9): 2072-9.
  15. Yu S., Yang X., Zhu Y., Xie F., Lu Y., Yu T. et al. Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: Comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex. Sci. Rep. 2015; 5: 7830. doi: 10.1038/srep07830.
  16. Tieszen Ch.R., Goyeneche A.A., Brandhagen B.A.N., Ortbahn C.T., Telleria C.M. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer. 2011; 11: 207. Available at: http://www.biomedcentral.com/1471-2407/11/207

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies